Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind sham-controlled study of JZB32 for symptomatic vitreomacular traction
CTR20263104Phase 2Active
- Sponsor
- Chengdu Zeyan Biotechnology
- Start
- Aug 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human truncated plasmin in vitreomacular traction (VMT), sponsored by Chengdu Zeyan Biotechnology. Started Aug 2026; status: active.
02
Drugs
recombinant human truncated plasmin
03
Conditions
vitreomacular traction (VMT)
Beyond the preview
Go deeper on CTR20263104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263104.